Becker's Healthcare November 18, 2024
Elizabeth Gregerson

The GLP-1 tirzepatide, the active ingredient in Eli Lilly’s Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity, according to a study published Nov. 16 in The New England Journal of Medicine and presented at the American Heart Association’s annual Scientific Sessions.

“While tirzepatide causes considerable weight loss, research is lacking on its effects on cardiovascular outcomes,” lead study author Milton Packer, MD, distinguished scholar in cardiovascular science at Dallas-based Baylor University Medical Center in Dallas and visiting professor at Imperial College in London, said in a Nov. 16 news release from AHA.

As part of the international Summit trial, researchers studied the effects tirzepatide had on participants’ health and the rate of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, Conferences / Podcast, Patient / Consumer, Pharma / Biotech, Provider, Trends
Related Articles:
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
A Biologist Explains The ‘Weird’ Habits Of People Who Live To 100+ Years Old

Share This Article